303 related articles for article (PubMed ID: 32898857)
21. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
22. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
23. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
25. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
26. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
27. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
28. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
Li S
Leuk Lymphoma; 2008 Jan; 49(1):19-26. PubMed ID: 18203007
[TBL] [Abstract][Full Text] [Related]
29. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
30. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
32. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
34. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
36. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
Nakajima A; Tauchi T; Ohyashiki K
Leukemia; 2001 Jun; 15(6):989-90. PubMed ID: 11417489
[No Abstract] [Full Text] [Related]
37. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
39. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
40. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
